Caxton Advantage Life Sciences Fund

Caxton Advantage Life Sciences Fund operates as a venture capital entity exclusively focused on the life sciences sector. The fund specializes in providing capital to late-stage clinical development companies, encompassing both privately-held and micro-cap public enterprises. Its investment strategy targets businesses poised for significant clinical milestones and nearing commercialization within biotechnology and pharmaceuticals.

This specialized fund is managed by Valence Life Sciences, an investment firm established in 2012 by Dr. Rachel Leheny and Eric Roberts. Both Leheny and Roberts previously at Caxton Advantage Venture Partners. Their founding insight was creating a dedicated vehicle supporting life sciences companies progressing beyond early research, emphasizing clinical validation and market readiness.

Caxton Advantage Life Sciences Fund primarily backs innovative life science ventures in advanced clinical stages requiring funding for pivotal trials and regulatory pathways. The firm’s mission aims to foster innovation and expedite the development of novel therapies and technologies addressing unmet medical needs, generating value and advancing global healthcare.